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Introduction
The autosomal recessive substitution of valine for glutamic acid at position six of the "-globin chain of hemoglobin in sickle cell anemia results in mutant hemoglobin S that polymerizes upon deoxygenation. This is the central event that leads to hemolysis, vaso-occlusive episodes and numerous acute and chronic complications. Pulmonary hypertension may develop in most forms of hereditary and chronic hemolytic anemia, [1] [2] [3] [4] suggesting that there is a clinical syndrome of hemolysis-associated pulmonary hypertension. During intravascular hemolysis, hemoglobin and arginase-1 are released into the plasma from erythrocytes. Plasma cell-free hemoglobin scavenges nitric oxide and arginase-1 depletes the plasma of arginine, the obligate substrate for nitric oxide synthase, and these processes may produce a hemolysis-linked state of decreased nitric oxide bioavailability and vascular dysfunction. [5] [6] [7] Cross-sectional studies have found associations between the degree of hemolysis and markers of pulmonary artery pressure in individuals with sickle cell disease. 8, 9 Elevated tricuspid regurgitation velocity measured by echocardiography occurs in up to one-third of adults with sickle cell disease, correlates with elevated systolic pulmonary artery pressure and is associated with increased morbidity and mortality. 8, 10, 11 However, whether high degrees of hemolysis lead to pulmonary vascular complications in sickle cell anemia is controversial. 12 Left ventricular diastolic dysfunction is a frequent finding in sickle cell disease adults with right heart catheterization-documented pulmonary hypertension 13 and is also an independent predictor of death.
14 Elevated tricuspid regurgitation velocity 9,15-21 and left ventricular diastolic dysfunction 22 develop in children with sickle cell disease but the clinical importance is not clear. 16, 22, 23 In particular, whether screening and intervention for these complications should begin in childhood is not known. In the few longitudinal studies of cardiopulmonary complications in children with sickle cell disease that have been reported, 18, 21, 24 an association with mortality during the short duration of follow up has not been observed. The Pulmonary Hypertension and the Hypoxic $ Response in SCD (PUSH) study is a prospective, ongoing, multicenter screening and longitudinal investigation of children and adolescents with sickle cell disease. Here we describe the consequences of increased hemolytic rate, elevated tricuspid regurgitation velocity, and left ventricular dysfunction among 160 children with sickle cell anemia followed for a median of 22 months, the largest such prospective screening and follow-up cohort study reported to date.
Design and Methods
Study participants and study design
The institutional review boards of all participating institutions approved the study and written consent was obtained for all participants. Of 269 participants aged 3-20 years with sickle cell anemia (hemoglobin SS) who had clinical evaluation, echocardiography and six-minute walk test performed at steady-state as previously described, 9 follow-up information was available for 166 participants at the time of this report, giving a follow-up success rate of 62%. The other 103 children did not have follow-up studies because of a recent hospitalization, failure to keep an appointment, failure to agree to follow-up or inability to make contact to schedule the follow-up.
The children having follow-up did not differ significantly from those not having follow-up in terms of baseline tricuspid regurgitation velocity, E/Etdi, hemolytic markers, hemoglobin concentration or six-minute walk distance. In addition six children were excluded from the present report because their follow-up occurred less than 12 months from recruitment. 
Molecular genetic testing
Hemoglobin S genotyping was conducted at ARUP Laboratories (Salt Lake City, UT, USA) using loci-spanning probe -PCR as described.
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Follow-up information
Follow-up information included laboratory measurements, tricuspid regurgitation velocity, mitral valve E/Etdi ratio, left ventricular internal diastolic dimension (LVIDD) z-score, and six-minute walk distance at the time of follow-up, as well as clinical events such as death, stroke, acute chest syndrome, and blood transfusions in the time interval since the baseline observations. We & analyzed evolution of six-minute walk distance and of echocardiographically-determined tricuspid regurgitation velocity between the initial study and the follow-up evaluation.
Statistical analysis
Principal component was used to derive a hemolytic component from absolute reticulocyte count and from age-adjusted values for lactate dehydrogenase, aspartate transaminase and bilirubin that was adjusted for each site of enrollment. This component represents a normalized standard distribution with a mean value of 0 and reflects the maximal shared variance among the variables from which it is derived. Principal component analysis is useful for studying underlying mechanisms reflected in individual biological measurements. 36, 37 In the present study, additional value to the principle component was that it accounted for age-related changes in markers such as lactate dehydrogenase and for different reference ranges among the participating institutions.
For continuous variables that did not follow a normal distribution, the best transformation to a normal distribution was made for statistical analyses. Continuous variables were compared between screening and follow-up with the paired t-test. Logistic regression or analysis of variance models as appropriate were used to assess baseline predictors of six-minute walk distance and follow-up tricuspid regurgitation velocity. As prospectively planned, the influence of hemolytic markers on these outcome variables was assessed in these models. For the analysis of decline in six-minute walk distance during follow-up, the observed distances were agestandardized by regression. 
Results
Baseline characteristics of the study cohort (Table 1) At baseline, the median age of the 160 participants was 13 years and 51% of the participants were females. Forty-nine percent were receiving hydroxyurea therapy and 18% were on a chronic transfusion program, usually for elevated transcranial Doppler velocity values or history of stroke. Baseline tricuspid regurgitation velocity was not measurable in 11 participants and was 2.60 m/sec or higher in 21 (14.1%) of 149 participants. Baseline mitral valve E/Etdi was 9.23 or higher in 12 (7.7%) of 156 participants. The median duration of follow-up was 22 months with a range of 13-35 months. Fifty-six (35%) of the subjects were receiving neither hydroxyurea nor chronic transfusion; among these the prevalence of tricuspid regurgitation velocity !2.60 m/sec was 14.0% and of E/Etdi !9.23 was 11.3%. The prevalence of elevated tricuspid regurgitation velocity or elevated E/Etdi according to hydroxyurea treatment or chronic transfusion therapy is shown in Table 2 . The prevalence of elevated tricuspid regurgitation velocity was higher in children receiving chronic transfusion therapy and the prevalence of elevated E/Etdi was lower in children receiving hydroxyurea therapy.
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Correlation of baseline and follow-up results
In our previously published cross-sectional analysis of baseline data, we observed significant independent associations of higher hemolytic component and lower hemoglobin oxygen saturation with elevated tricuspid regurgitation velocity. 9 In the present study we evaluated how baseline screening observations correlate with repeat observations nine to 35 months later and found the expected significant relationships for hemoglobin concentration (Figure 1a 
Evolution of six-minute walk distance during follow-up
To evaluate functional capacity, the six-minute walk distance was measured at both baseline and follow-up in 118 hemoglobin SS participants and the two measurements correlated significantly ( Figure 1g ). Among 111 hemoglobin SS patients, elevated baseline tricuspid regurgitation velocity was associated with a shorter follow-up six-minute walk distance (beta = -39.0, 95% CI=-3.6 to -74.5, P=0.031) after adjusting for baseline six-minute walk distance and duration of follow-up ( Figure 2a ). On the other hand, neither lower baseline hemoglobin concentration nor elevated E/Etdi ratio were associated with a shorter walk distance at follow-up (P=0.8 in each case). After age-standardization, the frequency of a 10% or greater decline in the six-minute walk distance during follow-up was 47% in participants with elevated tricuspid regurgitation velocity compared to 21% in those without elevated velocity (P = 0.033). By logistic regression, elevated baseline tricuspid regurgitation velocity was associated with an estimated 4.4-fold increase in the odds of a 10% or greater decline in six-minute walk distance during follow-up (95% CI=1.3-14.5; P=0.015) after adjusting for duration of follow-up ( Figure 2b ).
Neither treatment with hydroxyurea nor participation in a chronic transfusion program was a significant predictor of follow-up six-minute walk distance, and adjustment for these potential confounders did not affect the results.
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Increase in tricuspid regurgitation velocity during follow-up
The mean (SD) tricuspid regurgitation velocity at baseline in 149 participants with this measurement available was 2.33 (0.26) m/sec. Among 139 participants with tricuspid regurgitation velocity measurable at both baseline and follow-up, 24 (17.3%) had an increase in the velocity of one SD or more: 13.6% of participants with baseline hemolytic component below the median had such an increase compared to 20.6% of participants with baseline hemolytic component above the median. After adjustment for the duration of follow-up and baseline velocity, a hemolytic component above the median was associated with an estimated 9.0-fold increase in the odds of an increase in the tricuspid regurgitation velocity of one SD or more (95% CI= 1.9 -43.1; P = 0.006). Similar findings applied to the measurements from which the hemolytic component was derived. An LDH above the median was associated with an estimated 12.4-fold increase in the odds of an increase in the tricuspid regurgitation velocity of one SD or more (P = 0.004), an AST above the median with an estimated 6.6-fold increase in the odds (P = 0.011), a bilirubin above the median with an estimated 12.9-fold increase in the odds (P = 0.001), and a reticulocyte percent above the median with an estimated 10.4-fold increase in the odds (P = 0.007).
Forty-two patients on neither hydroxyurea nor chronic transfusion at baseline had tricuspid regurgitation velocity measured at both baseline and follow-up, and 10 (23.8%) had an increase of one SD or more. In this subgroup of participants on neither hydroxyurea nor chronic transfusion, a hemolytic component above the median was associated with an estimated 4.3-fold increase in the odds of an increase in the tricuspid regurgitation velocity of one SD or more after adjustment for the duration of follow-up and baseline velocity (95% CI = 0.3 -54.0; P = 0.3).
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Increase in mitral valve E/Etdi during follow-up
The mean (SD) E/Etdi at baseline in 156 participants with this measurement available was 6.82
(1.56). Among 145 participants with E/Etdi measurable at both baseline and follow-up, 17
(11.7%) had an increase in E/Etdi of one SD or more: 10.1% of participants with baseline hemolytic component below the median had such an increase compared to 14.3% of participants with baseline hemolytic component above the median. After adjustment for the duration of follow-up and baseline E/Etdi, a hemolytic component above the median was associated with an estimated 1.6-fold increase in the odds of an increase in the E/Etdi of one SD or more (95% CI = 0.5-4.5; P = 0.4).
Forty-seven patients on neither hydroxyurea nor chronic transfusion at baseline had E/Etdi measured at both baseline and follow-up, and 6 (12.8%) had an increase of one SD or more. In this subgroup of participants on neither hydroxyurea nor chronic transfusion, a hemolytic component above the median was associated with an estimated 4.4-fold increase in the odds of an increase in E/Etdi of one SD or more after adjustment for the duration of follow-up and baseline E/Etdi (95% CI = 0.4 -43.1; P = 0.2).
New development of elevated tricuspid regurgitation velocity elevation during follow-up
To assess the new development of elevated tricuspid regurgitation velocity during the study, we evaluated 119 participants without elevated tricuspid regurgitation velocity at baseline. Eighteen (26.2%) with higher hemolytic component. Sixteen of 115 children (13.9%) with E/Etdi ratio <9.23 developed elevated velocity during follow-up compared to 3 of 8 (28.6%) with E/Etdi ratio over this limit. In a logistic regression analysis, each 12-month interval of follow-up was associated with a 6.3-fold increase in the odds of newly developing elevated velocity during follow-up (95% CI 1.4-27.6; P=0.015), elevated hemolytic component at baseline with an estimated 9.0-fold increase in the odds (95% CI 1.8-44.8; P=0.008) (Figure 3a) , and elevated mitral valve E/Etdi ratio with an estimated 6.1-fold increase in the odds (95% CI 1.1-41.8; P=0.039) (Figure 3b ).
Pathway analysis of the relationships of hemolytic component, tricuspid regurgitation velocity and E/Etdi ratio with decline in six-minute walk distance (Figure 4)
In pathway analysis both baseline higher hemolytic component and increased E/Etdi ratio were significant predictors of elevated tricuspid regurgitation velocity at baseline and follow-up, and baseline elevated tricuspid regurgitation velocity was also a predictor of elevated velocity at follow-up. Both baseline and follow-up elevations of tricuspid regurgitation velocity were associated with higher risk of a 10% or more decline in the age-standardized six-minute walk distance. This model fits the data well (Chi-square = 8.6; degrees of freedom = 10; P = 0.6 and Root Mean Square Error of Approximation = 0.0; 90% confidence interval 0.0 -0.08).
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Adverse outcomes at follow-up according to baseline hemolytic component and tricuspid regurgitation velocity
Prospectively chosen two-year outcomes in this study included death, stroke, acute chest syndrome and blood transfusion requirement during the follow-up interval. New events, i.e.
events that occurred during the follow-up interval in subjects not reporting the complication at baseline, are summarized in Table 3 . None of 133 participants without a past history of stroke developed a stroke during the follow-up period. Two of 160 participants (1.3%) died during the follow-up period. One of these children had elevated hemolytic component and history of stroke at baseline but neither of them was observed to have elevated baseline tricuspid regurgitation velocity or mitral valve E/Etdi ratio. Elevated mitral valve E/Etdi ratio, but not increased hemolytic component or elevated tricuspid regurgitation velocity, was associated with higher proportion of new acute chest syndrome episodes (P<0.001) and new transfusion (P=0.043).
Discussion
In our previously reported prospective cross sectional study of 310 children and adolescents with sickle cell disease at steady state, 9 we found an 11.0% prevalence of elevated tricuspid regurgitation velocity (!2.60 m/sec). The prevalence was 14.0% among children with sickle cell anemia (homozygous hemoglobin SS genotype) and 3.6% among children with other genotypes. We now report that, in the follow-up of the children with sickle cell anemia, baseline elevation of tricuspid regurgitation velocity was predictive of a decline in the age-standardized six-minute walk distance during a follow-up interval that ranged from 13 to 35 months. Further research should determine whether an elevation of tricuspid regurgitation velocity may also identify a subset of children and adolescents at heightened risk for becoming adults with high pulmonary arterial pressures, low six-minute walk distance, 39 and high rate of early mortality. 8, 10, 11 !$ Also, among hemoglobin SS participants without initial elevation of tricuspid regurgitation velocity, we observed that a high hemolytic component and elevated mitral valve E/Etdi ratio at baseline and the duration of follow-up were independent predictors of the new development of elevated tricuspid regurgitation velocity at follow-up. Thus, our results are consistent with agerelated increases in the prevalence of high pulmonary artery pressure that are linked to a high intensity of hemolysis and to left ventricular diastolic dysfunction. The derivation of a hemolytic component and logistic regression analysis allowed us to find a statistically stronger contribution of hemolysis than that of anemia to a high tricuspid regurgitation velocity. This is consistent with our previous model based on biochemical evidence of nitric oxide scavenging by plasma hemoglobin and arginine depletion by plasma arginase, plasma hemoglobin and arginase being products of intravascular red blood cell breakdown. 5, 6 The additional finding that elevated E/Etdi ratio was an independent predictor of the new development of elevated tricuspid regurgitation velocity in this cohort parallels findings in adults with sickle cell disease that elevated pulmonary capillary wedge pressure is a frequent accompaniment of right heart catheterizationdocumented pulmonary hypertension. 13 Because of the low prevalence of elevated mitral valve E/Etdi ratio in the present cohort, hemolytic component was a more important risk factor than elevated mitral valve E/Etdi ratio for new onset of elevated tricuspid regurgitation velocity, the population attributable risks being 73% versus 26%.
Pathway analysis was consistent with the possibility that the degree of hemolysis and elevated left ventricular filling pressure at baseline together contributed to elevation of tricuspid regurgitation of velocity at both baseline and follow-up. In turn, these elevations in estimated pulmonary artery pressure were more directly associated with decline in functional capacity during follow-up.
There are several limitations to our study. First, the median follow-up interval of 22 months, which was dictated by the limited period of funding, was short and may have prevented identifying clinically important associations of elevations of hemolysis and tricuspid regurgitation !% velocity with other adverse events. Second, the numbers of participants having elevations of tricuspid regurgitation velocity or mitral valve E/Etdi at baseline were relatively small. To fully characterize the clinical associations of elevations of hemolysis and tricuspid regurgitation velocity in children with sickle cell anemia will require the longitudinal study of a larger cohort than was included in this report. Third, the tricuspid regurgitation velocity is an indirect reflection of systolic pulmonary artery pressure that can vary from day to day. A preliminary report in adult sickle cell disease individuals suggested that the specificity of a tricuspid regurgitation velocity of 2.8 m/sec for predicting high mean pulmonary artery pressure was 50%. 40 Our results showed a strong correlation between two measurements taken about two years apart, but a single screening elevated measurement was confirmed on repeat testing in less than half of the cases. Fourth, the degree of hemolysis may be affected considerably by a recent blood transusion. Therefore, in this study, blood collection, echocardiogram and six-minute walk testing were performed at least three weeks after a blood transfusion.
In summary, our results indicate that elevated tricuspid regurgitation velocity may be a biomarker in children with sickle cell anemia that is associated with a decline in exercise capacity and that increases in prevalence with age, especially in the presence of high hemolytic rate or increased left ventricular filling pressure. Further research should determine whether elevated tricuspid regurgitation velocity and mitral valve E/Etdi ratio identify children with sickle cell anemia who will become adults with high hemolytic rate and elevated tricuspid regurgitation velocity, a group known to be at high risk for early mortality.!The clinical importance of pulmonary hypertension in sickle cell disease and the usefulness of elevated tricuspid regurgitation velocity to predict pulmonary hypertension in sickle cell disease are controversial.
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Nevertheless we propose that accumulated evidence may justify consideration of clinical trials directed at risk reduction in an early pre-symptomatic stage in childhood to prevent the development of clinically significant elevation of tricuspid regurgitation velocity in adulthood.
Potential modalities to be tested would include hydroxyurea or a blood transfusion program.
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This proposed approach is conceptually similar in the general population to identifying and treating systemic hypertension in children in order to reduce cardiovascular risks in adulthood.
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